IBT Bioservices Transforms Identity, Elevates Focus on Contract Research Services
[Maryland, January 2024] – IBT Bioservices, a renowned figure in the Biocapital region’s life sciences landscape, proudly announces its rebranding from Integrated Biotherapeutics. Effective February 2023, IBT Bioservices unveils a revitalized identity, reinforcing its commitment to excellence in Contract Research Organization (CRO) services.
This strategic evolution underscores IBT Bioservices’ dedication to delivering top-tier preclinical and clinical research solutions. Simultaneously, the company has strategically repositioned its pioneering R&D portfolio of vaccines & therapeutics into a spin-off company called AbVacc, Inc., intensifying its focus on advancing the frontiers of combating infectious disease in the biotech and pharmaceutical sectors.
Strategically positioned within the Washington DC/Maryland/Virginia region, IBT Bioservices leverages cutting-edge facilities and unmatched expertise to offer comprehensive research solutions. The company’s transition solidifies its pledge to serve as a trusted ally in accelerating drug development and catalyzing transformative therapies.
“The company reorganization marks a pivotal moment in our journey, empowering us to better serve our clients’ evolving needs,” commented Javad M. Aman, Founder of Integrated BioTherapeutics. “This transition reinforces our dedication to innovation, ensuring that the company continues to deliver exceptional CRO services to our partners. Additionally, we are excited to announce the launch of a new website in 2024 and client portal, consolidating our services under one cohesive umbrella to streamline and enhance the client experience.”
Specializing in diverse services including preclinical research, in vitro and cell-based assay development, toxicology studies, immunology assays, and animal studies, IBT Bioservices now offers a more focused, client-centric approach. This streamlined strategy enables the company to swiftly adapt to industry demands while maintaining an unwavering commitment to quality. With a dedication to advancing scientific excellence, we are thrilled to announce the appointment of Dr. Frederick Holtsberg as the Chief Scientific Officer (CSO) at IBT Bioservices.
IBT Bioservices is also preparing for a significant milestone in 2025. “We are thrilled to be introducing clinical research testing services, expanding our capabilities to facilitate a more comprehensive approach to the development of vaccines and therapeutics.” commented Dr. Holtsberg.
As IBT Bioservices enters this transformative phase, the company stays resolute in its mission to spearhead innovations and establish industry standards as it repositions itself as a comprehensive, all-in-one CRO solution provider.
For further information or media inquiries, please contact IBT Bioservices at services@IBTBioservices.com.
About IBT Bioservices:
IBT Bioservices is a leading Contract Research Organization (CRO) specializing in preclinical and clinical research services within the Biocapital region. Driven by innovation and client-centricity, IBT Bioservices is dedicated to propelling the development of modern therapeutics and fostering breakthroughs in the life sciences industry.
